Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

In this week's STATus Report, STAT reporters Jason Mast and Damian Garde discuss the challenges facing Moderna — and what could be in store for its third act.

In the past week, Moderna reported third-quarter 2025 earnings with revenue at US$1.02 billion, down sharply from the ...

The pharmaceutical group, which has been grappling with weakening post-pandemic demand for COVID-19 vaccines, posted a 45% decline in quarterly revenue to $1.02 billion. However, Wall Street ...

What Happened? A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing concerns about its ...

Investing.com - Moderna (NASDAQ: MRNA) reported third quarter EPS of $-0.51, $1.54 better than the analyst estimate of $-2.05. Revenue for the quarter came in at $1.02B versus the consensus estimate ...

Moderna ( (MRNA)) has provided an update. On November 12, 2025, Moderna, Inc. held a Special Meeting of Shareholders where two proposals were approved. The first was a one-time stock option exchange ...

The story of the pharmaceutical company Moderna almost reads like a Hollywood screenplay. In its relatively short life, it ...

Learn more about whether Moderna, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Moderna beats Q3 forecasts as cost-cutting offsets weaker COVID vaccine sales and new mRNA cancer trials advance.

The headline numbers for Moderna (MRNA) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street ...